Syros Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Syros Pharmaceuticals has a total shareholder equity of $-11.1M and total debt of $41.1M, which brings its debt-to-equity ratio to -369.3%. Its total assets and total liabilities are $85.0M and $96.1M respectively.
Key information
-369.3%
Debt to equity ratio
US$41.08m
Debt
| Interest coverage ratio | n/a |
| Cash | US$58.28m |
| Equity | -US$11.12m |
| Total liabilities | US$96.12m |
| Total assets | US$85.00m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0LC7 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 0LC7 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 0LC7 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 0LC7's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0LC7 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 0LC7 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.6% each year